Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

Recent & Breaking News (NDAQ:PMN)

ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved

GlobeNewswire June 30, 2023

CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time

GlobeNewswire June 29, 2023

ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights

GlobeNewswire May 15, 2023

ProMIS Neurosciences (TSX:PMN) notches FDA clearance for Alzheimer's disease treatment

Jocelyn Aspa May 8, 2023

ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer's Disease

GlobeNewswire May 8, 2023

Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer's Disease

GlobeNewswire April 25, 2023

ProMIS Neurosciences (TSX:PMN) attends 75 American Academy of Neurology

Brieanna McCutcheon  April 24, 2023

ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer's Disease and ALS at American Academy of Neurology Annual Meeting

GlobeNewswire April 24, 2023

ProMIS Neurosciences (TSX:PMN) files application for new Alzheimer’s vaccine

Jonathon Brown April 10, 2023

ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310

GlobeNewswire April 10, 2023

Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023

GlobeNewswire March 29, 2023

ProMIS Neurosciences (TSX:PMN) to present at the American Academy of Neurology 2023

Brieanna McCutcheon  March 13, 2023

ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting

GlobeNewswire March 13, 2023

ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023

GlobeNewswire March 13, 2023

ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent Highlights

GlobeNewswire March 8, 2023

Promis Neurosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference

GlobeNewswire March 8, 2023

ProMIS Neurosciences Announces Third Quarter 2022 Financial Results and Recent Highlights

GlobeNewswire November 14, 2022

ProMIS Neurosciences (TSX:PMN) closes US$7.4M private placement

John Ballem  October 12, 2022

ProMIS Neurosciences Announces Closing of US $7.4 Million Private Placement

GlobeNewswire October 12, 2022

ProMIS Neurosciences (TSX:PMN) appoints Dr. Gail Farfel as Chief Executive Officer

John Ballem  September 13, 2022